Protara Therapeutics, Inc. — Director's Dealing 2017

Jul 5, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PROTEON THERAPEUTICS INC (PRTO)
CIK: 0001359931
Period of Report: 2017-06-30

Reporting Person: Kowalsky Matthew Paul (VP, Legal and Secretary)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-06-30	Common Stock	A	10000	$1.296	Acquired	13097	Direct

Footnotes

F1: The shares were acquired under the Issuer's 2014 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).